It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Importance: Vaccinations are paramount to halt the COVID-19 pandemic, and safety data are essential to determine the risk-benefit ratio of each COVID-19 vaccine.
Objective: To evaluate the association between the AZD1222, BNT162b2, and mRNA-1273 vaccines and subsequent thromboembolic and thrombocytopenic events.
Design, setting, and participants: This self-controlled case series used individual-level data from national registries in Norway, Finland, and Denmark. Participants included individuals with hospital contacts because of coronary artery disease, coagulation disorders, or cerebrovascular disease between January 1, 2020, and May 16, 2021.
Exposures: AZD1222, BNT162b2, or mRNA-1273 vaccine.
Main outcomes and measure: Relative rate (RR) of hospital contacts for coronary artery disease, coagulation disorders, or cerebrovascular disease in a 28-day period following vaccination compared with the control period prior to vaccination.
Results: We found 265 339 hospital contacts, of whom 112 984 [43%] were for female patients, 246 092 [93%] were for patients born in 1971 or earlier, 116 931 [44%] were for coronary artery disease, 55 445 [21%] were for coagulation disorders, and 92 963 [35%] were for cerebrovascular disease. In the 28-day period following vaccination, there was an increased rate of coronary artery disease following mRNA-1273 vaccination (RR, 1.13 [95% CI, 1.02-1.25]), but not following AZD1222 vaccination (RR, 0.92 [95% CI, 0.82-1.03]) or BNT162b2 vaccination (RR, 0.96 [95% CI, 0.92-0.99]). There was an observed increased rate of coagulation disorders following all 3 vaccines (AZD1222: RR, 2.01 [95% CI, 1.75-2.31]; BNT162b2: RR, 1.12 [95% CI, 1.07-1.19]; and mRNA-1273: RR, 1.26 [95% CI, 1.07-1.47]). There was also an observed increased rate of cerebrovascular disease following all 3 vaccines (AZD1222: RR, 1.32 [95% CI, 1.16-1.52]; BNT162b2: RR, 1.09 [95% CI, 1.05-1.13]; and mRNA-1273: RR, 1.21 [95% CI, 1.09-1.35]). For individual diseases within the main outcomes, 2 notably high rates were observed: 12.04 (95% CI, 5.37-26.99) for cerebral venous thrombosis and 4.29 (95% CI, 2.96-6.20) for thrombocytopenia, corresponding to 1.6 (95% CI, 0.6-2.6) and 4.9 (95% CI, 2.9-6.9) excess events per 100 000 doses, respectively, following AZD1222 vaccination.
Conclusions and relevance: In this self-controlled case series, there was an increased rate of hospital contacts because of coagulation disorders and cerebrovascular disease, especially for thrombocytopenia and cerebral venous thrombosis, following vaccination with AZD1222. Although increased rates of several thromboembolic and thrombocytopenic outcomes following BNT162b2 and mRNA-1273 vaccination were observed, these increases were less than the rates observed after AZD1222, and sensitivity analyses were not consistent. Confirmatory analysis on the 2 mRNA vaccines by other methods are warranted.
originally posted by: marg6043
I already have knowledge of two very close friends that developed brain bleeding that have been fully jabbed and followed on the boosters.
The first a female she works as a health care worker, soo she follow faithfully on the boosters, even when she already got Covid before the jabs started, her symptoms came out of nowhere, a severe headache been a nurse she knew it was not normal, soo she drove herself to the hospital and test found tiny clots in her brain, she was lucky, she spend two weeks in the hospital, but no irreversible damage to her brain.
The second a co worker of my husband, fully jabbed and boosterized, he waited too long after the initial head aches and now he is in rehabilitation, first he was diagnosed with a stroke, but after further test it was no his hart, he had also tiny blood clots in the brain, he have some damage but is expected to be fine.
Soo this is happening more and more often, a new symptom to the list of side effects of the jabs.
Results: We found 265 339 hospital contacts, of whom 112 984 [43%] were for female patients, 246 092 [93%] were for patients born in 1971 or earlier, 116 931 [44%] were for coronary artery disease, 55 445 [21%] were for coagulation disorders, and 92 963 [35%] were for cerebrovascular disease.
originally posted by: marg6043
I already have knowledge of two very close friends that developed brain bleeding that have been fully jabbed and followed on the boosters.
The first a female she works as a health care worker, soo she follow faithfully on the boosters, even when she already got Covid before the jabs started, her symptoms came out of nowhere, a severe headache been a nurse she knew it was not normal, soo she drove herself to the hospital and test found tiny clots in her brain, she was lucky, she spend two weeks in the hospital, but no irreversible damage to her brain.
The second a co worker of my husband, fully jabbed and boosterized, he waited too long after the initial head aches and now he is in rehabilitation, first he was diagnosed with a stroke, but after further test it was no his hart, he had also tiny blood clots in the brain, he have some damage but is expected to be fine.
Soo this is happening more and more often, a new symptom to the list of side effects of the jabs.
The incidence of VITT is not certain, but it appears to be extremely rare. A recent report in JACC found that cerebral vein thrombosis occurred in 3.6 per million people after the AstraZeneca COVID-19 vaccine and 0.9 per million people after Johnson & Johnson vaccine. For comparison, the rate of cerebral vein thrombosis is estimated at 207 per million in patients hospitalized with COVID-19 and 2.4 per million in the general population. The risk of death and serious outcomes of COVID-19 (including thrombosis) far outweigh the small risk of VITT.
Overall, the concept that vaccination may induce ITP is not new or without precedent. Thrombocytopenia was frequently seen in children exposed to a live attenuated (weakened) vaccine against measles. The average maximum fall in platelet counts approached 100,000 platelets per microliter; the maximum decrease was seen at 1 week after vaccination, and platelet counts generally returned to baseline levels within 3 weeks. Indirect evidence of viral infection of megakaryocytes was seen, suggestive of a component of impaired platelet production9. The attributable risk of ITP, generally mild and resolving within weeks or months, is estimated to be about one case per 40,000 doses of the vaccine against measles–mumps–rubella, which is only slightly higher than that noted after natural infection with the viruses that cause these diseases
originally posted by: quintessentone
a reply to: Kurokage
Not ignorant, rather denial of facts it seems.